A Randomized, Double-Blind Study to Assess the Optimal Duration of Doxycycline Treatment for Human Brucellosis
Open Access
- 15 December 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (12), 1776-1782
- https://doi.org/10.1086/426024
Abstract
Background. Human brucellosis is usually treated with a combination of tetracyclines and aminoglycosides. However, the optimal duration of therapy has not been clearly determined. Methods. We conducted a prospective, double-blind, randomized, multicenter study comparing treatment with doxycycline (100 mg po b.i.d.) for 30 days (30-day group) with the same dosage of doxycycline for 45 days (45-day group) in patients with brucellosis without endocarditis, spondylitis, or neurobrucellosis. All patients were treated with gentamicin (240 mg im once daily) for the first 7 days. Therapeutic outcome was evaluated by measuring relapse rates and drug safety. Results. Seventy-three patients were included in each group. During the first 45 days after treatment, the percentage of patients with relapse was significantly higher in the 30-day group than in the 45-day group (12.3% vs. 1.37%; relative risk, 9.00; 95% confidence interval [CI], 1.17–69.2; P = .017). Between day 45 after treatment and 12 months after treatment, no further significant differences were found in relapse rates between groups (9.38% in the 30-day group vs. 11.11% in the 45-day group; relative risk, 0.84; 95% CI, 0.31–2.30; P = .78). Overall, relapses occurred in 15 (20.55%) of 73 patients in the 30-day group and in 9 (12.33%) of 73 patients in the 45-day group (relative risk, 1.67; 95% CI, 0.78–3.56; P = .264). Compliance and adverse effects were comparable in the 2 groups. Conclusions. Doxycycline treatment for 45 days significantly decreased early relapse rates among adults with brucellosis without increasing adverse effects.Keywords
This publication has 10 references indexed in Scilit:
- Multivariate model for predicting relapse in human brucellosisJournal of Infection, 1998
- Failure of short antimicrobial treatments for human brucellosisAntimicrobial Agents and Chemotherapy, 1997
- Recognition and Optimum Treatment of BrucellosisDrugs, 1997
- Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades InfecciosasAntimicrobial Agents and Chemotherapy, 1995
- Characteristics of and Risk Factors for Relapse of Brucellosis in HumansClinical Infectious Diseases, 1995
- Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational studyJournal of Antimicrobial Chemotherapy, 1989
- Vaccines for Haemophilus influenzae type b as models for an otitis vaccineThe Pediatric Infectious Disease Journal, 1989
- Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosisAntimicrobial Agents and Chemotherapy, 1985
- Doxycycline Determination in Human Serum and Urine by High-Performance Liquid ChromatographyJournal of Pharmaceutical Sciences, 1979
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977